Source: International Congress 2017 – The Lancet commission on asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Bush (London, United Kingdom). Towards a cure for asthma. International Congress 2017 – The Lancet commission on asthma

Member's Comments

No comment yet.

Related content which might interest you: Success rate and safety of sputum induction in severe exacerbations of asthma Source: Eur Respir J 2002; 20: Suppl. 38, 93s Year: 2002 Ceruloplasmine efficacy in patients with asthma exacerbations Source: Annual Congress 2011 - Novel mechanisms in lung injury Year: 2011 Refining asthma treatment for mild asthma Source: Virtual Congress 2020 – Rethinking asthma Year: 2020 Incidence and remission of asthma and allergic rhinitis in Italy Source: Annual Congress 2010 - New insights in the epidemiology of asthma Year: 2010 Treatment and outcomes in patients with asthma and allergic rhinitis Source: Eur Respir J 2005; 26: Suppl. 49, 576s Year: 2005 Assesment of long-term omalizumab treatment in severe allergic asthma Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE Year: 2012 Endotypes of severe allergic asthma patients who clinically benefit from Anti-IgE therapy Source: International Congress 2018 – Studying novel biomarkers in asthma and COPD Year: 2018 Omalizumab therapy reduces asthma exacerbations in children with severe allergic (IgE-mediated) asthma irrespective of lung function at baseline Source: Annual Congress 2009 - Difficult asthma in children: diagnostic and therapeutic challenges Year: 2009 Omalizumab treatment reduces asthma exacerbations in children with moderate or severe persistent asthma Source: International Congress 2017 – Paediatric asthma: treatment modalities and behavioural issues Year: 2017 Real-life long-term omalizumab therapy in children with severe allergic asthma Source: Eur Respir J 2015; 46: 856-859 Year: 2015 Immunotherapy in severe asthma Source: ERS webinar 2021: Immunotherapy in severe asthma Year: 2021 Predictors of response to therapy with omalizumab in patients with severe allergic asthma–a real life study Source: International Congress 2017 – Monitoring asthma control Year: 2017 Effectiveness of omalizumab in improving quality of life in patients with ‘steroid-resistant‘ asthma and severe allergic rhinitis Source: Annual Congress 2012 - Clinical aspects and treatment of asthma and allergic respiratory diseases Year: 2012 Improvements in asthma control and quality of life with omalizumab in allergic (IgE-mediated) asthma patients Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma Year: 2012 The evaluations of allergic rhinitis symptoms in patients with asthma and allergic rhinitis with the addiing of montelukast in asthma treatment Source: Eur Respir J 2004; 24: Suppl. 48, 124s Year: 2004 Anti-IgE therapy with omalizumab decreases exacerbations in patients with poorly controlled moderate-to-severe allergic asthma Source: Eur Respir J 2003; 22: Suppl. 45, 203s Year: 2003 Anti-IgE treatment: An alternative for severe allergic occupational asthma Source: Annual Congress 2012 - Asthma and COPD at work: what are the effects of exposure and risk factors? Year: 2012 Improved symptom relief with omalizumab in the treatment of allergic rhinitis Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009